Render Target: STATIC
Render Timestamp: 2024-10-11T09:47:44.675Z
Commit: 56767fe525c928647c8401233a175d0d607d385d
XML generation date: 2024-09-18 13:54:14.845
Product last modified at: 2024-09-26T14:15:11.637Z
1% for the planet logo
PDP - Template Name: InTraSeq Conjugate
PDP - Template ID: *******e148868
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) Rabbit mAb (InTraSeq 3' Conjugate 3023) #76939

Filter:
  • SCA

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Rabbit IgG
    Application Key:
    • SCA-Single Cell Analysis 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Storage

    Supplied in PBS (pH 7.2), 2 mM EDTA, 0.05% Triton X-100, 2 mg/mL BSA, and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) Rabbit mAb (InTraSeq™ 3' Conjugate 3023) detects endogenous levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Tyr204. This antibody does not cross-react with the corresponding phosphorylated residues of either JNK/SAPK or p38 MAP kinase.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase.

    Background

    Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli, including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    10x Genomics, 10x, Feature Barcode, and Chromium are the trademarks or registered trademarks of 10x Genomics, Inc.
    InTraSeq is a trademark of Cell Signaling Technology, Inc.
    Subject to patents licensed from 10x Genomics, Inc. for use with single-cell (i.e., Chromium) 10x products.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.